Results 241 to 250 of about 27,163 (253)

Fingolimod

Reactions Weekly, 2013
openaire   +1 more source

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

Lancet Neurology, The, 2012
Virginia Devonshire, Eva Kubala Havrdova, Ludwig Kappos   +2 more
exaly  

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

Annals of Neurology, 2016
Peter Alping, Thomas Frisell, Jonatan Salzer   +2 more
exaly  

Fingolimod provides long‐term protection in rodent models of cerebral ischemia

Annals of Neurology, 2011
Muge Yemisci, Seo-Kyoung Hwang, James K Liao   +2 more
exaly  

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

Multiple Sclerosis Journal, 2012
Ju-Hong Min
exaly  

Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Annals of Neurology, 2015
Tomas Kalincik, Tim Spelman, Vilija G Jokubaitis   +2 more
exaly  

The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

CNS Drugs, 2015
Samuel F Hunter, Anthony T Reder
exaly  

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

Nature Reviews Drug Discovery, 2010
exaly  

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial

Lancet Neurology, The, 2018
Richard A C Hughes, Marinos C Dalakas, Eduardo Nobile-Orazio   +2 more
exaly  

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide

Annals of Neurology, 2014
Emanuela Colombo, Linda Chaabane, Jia Newcombe   +2 more
exaly